Clinical application of inhaled long-acting beta-2 agonists for obstructive airway diseases

Yuan Chih Chu, Tzuen-Ren Hsiue

Research output: Contribution to journalArticle

Abstract

Long-acting β2 agonists (LABA) are highly selective for relaxation of smooth muscle of bronchial wall. Inhaled form of LABA can produce local effect of bronchial tree, and less systemic effect. At present, two products of inhaled LABA are Salmeterol, and Formoterol. They had 12 hours duration of bronchial wall dilatation after inhaled. In clinical effects of these two drugs are similar, except Formoterol is rapid onset. For management of patients with asthma, LABA can decrease symptoms and signs, active glucocorticosteroid receptors, and decrease doses of inhaled corticosteroid. It could not administrate lonely due to little anti-inflammation effect. Combination of LABA and ICS in one device can improve lung function in moderate to severe persistent patients. Combination is superior or equal to concurrent therapy via two devices. LABA did not mask inflammation of airway and produce tolerance of short-acting β2 agonists in long-term using. For management of patients with chronic obstructive pulmonary disease (COPD), LABA role is not really clear at present. According GOLD criteria, they can prescribe for moderate to severe patients. LABA can decrease symptoms and signs, and improve lung function and quality of life in long-term using. LABA may induce cardiac arrhythmia in patients pre-existing arrhythmia and transient hypoxemia in patients with PaO2 >59 mmHg. In spite of these adverse effects, they are superior or equal to anticholinergics in management of COPD. LABA are first choice for management of patients with poor control COPD. In conclusions, LABA can free symptoms and sings and improve lung function in moderate to severe persistent asthma. Combination is superior or equal to concurrent therapy in patents with asthma. LABA or anticholinergics can consider first choice therapy drugs in patients with moderate to severe COPD.

Original languageEnglish
Pages (from-to)269-275
Number of pages7
JournalJournal of Internal Medicine of Taiwan
Volume13
Issue number6
Publication statusPublished - 2002

Fingerprint

Chronic Obstructive Pulmonary Disease
Asthma
Cholinergic Antagonists
Lung
Signs and Symptoms
Cardiac Arrhythmias
Inflammation
Equipment and Supplies
Patents
Masks
Smooth Muscle
Dilatation
Adrenal Cortex Hormones
Quality of Life
Drug Therapy
Therapeutics
Pharmaceutical Preparations
Formoterol Fumarate

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{ecd8ed20cc6e487cb7cb1dc6d9bb9ccb,
title = "Clinical application of inhaled long-acting beta-2 agonists for obstructive airway diseases",
abstract = "Long-acting β2 agonists (LABA) are highly selective for relaxation of smooth muscle of bronchial wall. Inhaled form of LABA can produce local effect of bronchial tree, and less systemic effect. At present, two products of inhaled LABA are Salmeterol, and Formoterol. They had 12 hours duration of bronchial wall dilatation after inhaled. In clinical effects of these two drugs are similar, except Formoterol is rapid onset. For management of patients with asthma, LABA can decrease symptoms and signs, active glucocorticosteroid receptors, and decrease doses of inhaled corticosteroid. It could not administrate lonely due to little anti-inflammation effect. Combination of LABA and ICS in one device can improve lung function in moderate to severe persistent patients. Combination is superior or equal to concurrent therapy via two devices. LABA did not mask inflammation of airway and produce tolerance of short-acting β2 agonists in long-term using. For management of patients with chronic obstructive pulmonary disease (COPD), LABA role is not really clear at present. According GOLD criteria, they can prescribe for moderate to severe patients. LABA can decrease symptoms and signs, and improve lung function and quality of life in long-term using. LABA may induce cardiac arrhythmia in patients pre-existing arrhythmia and transient hypoxemia in patients with PaO2 >59 mmHg. In spite of these adverse effects, they are superior or equal to anticholinergics in management of COPD. LABA are first choice for management of patients with poor control COPD. In conclusions, LABA can free symptoms and sings and improve lung function in moderate to severe persistent asthma. Combination is superior or equal to concurrent therapy in patents with asthma. LABA or anticholinergics can consider first choice therapy drugs in patients with moderate to severe COPD.",
author = "Chu, {Yuan Chih} and Tzuen-Ren Hsiue",
year = "2002",
language = "English",
volume = "13",
pages = "269--275",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "Society of Internal Medicine of Taiwan",
number = "6",

}

Clinical application of inhaled long-acting beta-2 agonists for obstructive airway diseases. / Chu, Yuan Chih; Hsiue, Tzuen-Ren.

In: Journal of Internal Medicine of Taiwan, Vol. 13, No. 6, 2002, p. 269-275.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical application of inhaled long-acting beta-2 agonists for obstructive airway diseases

AU - Chu, Yuan Chih

AU - Hsiue, Tzuen-Ren

PY - 2002

Y1 - 2002

N2 - Long-acting β2 agonists (LABA) are highly selective for relaxation of smooth muscle of bronchial wall. Inhaled form of LABA can produce local effect of bronchial tree, and less systemic effect. At present, two products of inhaled LABA are Salmeterol, and Formoterol. They had 12 hours duration of bronchial wall dilatation after inhaled. In clinical effects of these two drugs are similar, except Formoterol is rapid onset. For management of patients with asthma, LABA can decrease symptoms and signs, active glucocorticosteroid receptors, and decrease doses of inhaled corticosteroid. It could not administrate lonely due to little anti-inflammation effect. Combination of LABA and ICS in one device can improve lung function in moderate to severe persistent patients. Combination is superior or equal to concurrent therapy via two devices. LABA did not mask inflammation of airway and produce tolerance of short-acting β2 agonists in long-term using. For management of patients with chronic obstructive pulmonary disease (COPD), LABA role is not really clear at present. According GOLD criteria, they can prescribe for moderate to severe patients. LABA can decrease symptoms and signs, and improve lung function and quality of life in long-term using. LABA may induce cardiac arrhythmia in patients pre-existing arrhythmia and transient hypoxemia in patients with PaO2 >59 mmHg. In spite of these adverse effects, they are superior or equal to anticholinergics in management of COPD. LABA are first choice for management of patients with poor control COPD. In conclusions, LABA can free symptoms and sings and improve lung function in moderate to severe persistent asthma. Combination is superior or equal to concurrent therapy in patents with asthma. LABA or anticholinergics can consider first choice therapy drugs in patients with moderate to severe COPD.

AB - Long-acting β2 agonists (LABA) are highly selective for relaxation of smooth muscle of bronchial wall. Inhaled form of LABA can produce local effect of bronchial tree, and less systemic effect. At present, two products of inhaled LABA are Salmeterol, and Formoterol. They had 12 hours duration of bronchial wall dilatation after inhaled. In clinical effects of these two drugs are similar, except Formoterol is rapid onset. For management of patients with asthma, LABA can decrease symptoms and signs, active glucocorticosteroid receptors, and decrease doses of inhaled corticosteroid. It could not administrate lonely due to little anti-inflammation effect. Combination of LABA and ICS in one device can improve lung function in moderate to severe persistent patients. Combination is superior or equal to concurrent therapy via two devices. LABA did not mask inflammation of airway and produce tolerance of short-acting β2 agonists in long-term using. For management of patients with chronic obstructive pulmonary disease (COPD), LABA role is not really clear at present. According GOLD criteria, they can prescribe for moderate to severe patients. LABA can decrease symptoms and signs, and improve lung function and quality of life in long-term using. LABA may induce cardiac arrhythmia in patients pre-existing arrhythmia and transient hypoxemia in patients with PaO2 >59 mmHg. In spite of these adverse effects, they are superior or equal to anticholinergics in management of COPD. LABA are first choice for management of patients with poor control COPD. In conclusions, LABA can free symptoms and sings and improve lung function in moderate to severe persistent asthma. Combination is superior or equal to concurrent therapy in patents with asthma. LABA or anticholinergics can consider first choice therapy drugs in patients with moderate to severe COPD.

UR - http://www.scopus.com/inward/record.url?scp=0036934197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036934197&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 269

EP - 275

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 6

ER -